Παρασκευή 2 Ιουνίου 2017

Abciximab-induced delayed profound thrombocytopaenia

Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was eventually diagnosed with abciximab-induced delayed thrombocytopaenia. This case outlines the importance of close follow-up of these patients to prevent serious adverse events.



http://ift.tt/2s150KZ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου